Background: Approximately 30 % of breast cancer patients receive chemotherapy, yet little is known about influences of current regimens on circulating lymphocyte levels and phenotypes. Similarly, clinico-pathological factors that modify these influences, and implications for future immune health remain mainly unexplored. Methods: We used flow-cytometry to assess circulating lymphocyte levels and phenotypes in 88 primary breast cancer patients before chemotherapy and at time-points from 2 weeks to 9 months after chemotherapy completion. We examined circulating titres of antibodies against pneumococcal and tetanus antigens using ELISAs. Results: Levels of B, T and NK cells were significantly reduced 2 weeks after chemotherapy (p < 0.001). B c...
Background: We have previously shown lymphocyte density, measured using computational pathology, is...
Background: The phase II neo-adjuvant clinical trial ICORG10-05 (NCT01485926) compared chemotherapy ...
Background: The phase II neo-adjuvant clinical trial ICORG10-05 (NCT01485926) compared chemotherapy ...
Background: Approximately 30 % of breast cancer patients receive chemotherapy, yet little is known a...
PURPOSE: To identify potential immune targets in post-neoadjuvant chemotherapy (NAC)-resistant tripl...
Background Adaptive immunity is initiated by T-cell receptor (TCR) engagement with cognate tumor ant...
Background Adaptive immunity is initiated by T-cell receptor (TCR) engagement with cognate tumor ant...
Abstract Background How the immune microenvironment c...
Background: Pre-treatment tumour-associated lymphocytes (TILs) and stromal lymphocytes (SLs) are ind...
Background: Pre-treatment tumour-associated lymphocytes (TILs) and stromal lymphocytes (SLs) are ind...
Background: Immune escape of tumor cells is a new hallmark of cancer in general, and breast cancer, ...
Introduction: It is widely understood that the T-lymphocyte is closely linked to prognosis and trea...
PURPOSE: To identify potential immune targets in post-neoadjuvant chemotherapy (NAC)-resistant tripl...
Abstract Purpose: To identify potential immune t...
BACKGROUND: Chemotherapy-induced immune suppression has mainly been studied in patients with advanc...
Background: We have previously shown lymphocyte density, measured using computational pathology, is...
Background: The phase II neo-adjuvant clinical trial ICORG10-05 (NCT01485926) compared chemotherapy ...
Background: The phase II neo-adjuvant clinical trial ICORG10-05 (NCT01485926) compared chemotherapy ...
Background: Approximately 30 % of breast cancer patients receive chemotherapy, yet little is known a...
PURPOSE: To identify potential immune targets in post-neoadjuvant chemotherapy (NAC)-resistant tripl...
Background Adaptive immunity is initiated by T-cell receptor (TCR) engagement with cognate tumor ant...
Background Adaptive immunity is initiated by T-cell receptor (TCR) engagement with cognate tumor ant...
Abstract Background How the immune microenvironment c...
Background: Pre-treatment tumour-associated lymphocytes (TILs) and stromal lymphocytes (SLs) are ind...
Background: Pre-treatment tumour-associated lymphocytes (TILs) and stromal lymphocytes (SLs) are ind...
Background: Immune escape of tumor cells is a new hallmark of cancer in general, and breast cancer, ...
Introduction: It is widely understood that the T-lymphocyte is closely linked to prognosis and trea...
PURPOSE: To identify potential immune targets in post-neoadjuvant chemotherapy (NAC)-resistant tripl...
Abstract Purpose: To identify potential immune t...
BACKGROUND: Chemotherapy-induced immune suppression has mainly been studied in patients with advanc...
Background: We have previously shown lymphocyte density, measured using computational pathology, is...
Background: The phase II neo-adjuvant clinical trial ICORG10-05 (NCT01485926) compared chemotherapy ...
Background: The phase II neo-adjuvant clinical trial ICORG10-05 (NCT01485926) compared chemotherapy ...